Toxic epidermal necrolysis and Stevens-Johnson syndrome

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 5, Issue 6, 2005, Pages 555-558

  Hussein, Walayat ^a   Craven, Nicholas M ^a  

^a BURNLEY GENERAL HOSPITAL   (United Kingdom)

Author keywords

Education; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORAMPHENICOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; LAMOTRIGINE; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; SULFONAMIDE; VALPROIC ACID;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; PAIN; PATIENT MONITORING; PLASMAPHERESIS; REVIEW; SKIN BIOPSY; STEROID THERAPY; STEVENS JOHNSON SYNDROME; SYNDROME DELINEATION; TOXIC EPIDERMAL NECROLYSIS;

EID: 29244484428     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.5-6-555     Document Type: Review

References (29)

1. Roujeau JC, Kelly JP, Naldi L, Rzany B et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333: 1600-7.
2. Roujeau JC, Guillaume JC, Fahre JP, Penso D et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126:37-42.
3. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993;129:1059.
4. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26:567-74.
5. Roujeau JC, Huynh TN, Bracq C, Guillaume JC et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123: 1171-3.
6. Wolkenstein P, Charue D, Laurent P, Revuz J et al. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995; 131:544-51.
7. Revuz J, Penso D, Roujeau JC, Guillaume JC et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
8. Paul C, Wolkenstein P, Adle H, Wechsler J et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4.
9. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999;79:288-90.
10. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Pierard GE. Macrophages and tumour necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-8.
11. Wehrli P, Viard I, Bullani R, Tschopp J, French LE. Death receptors in cutaneous biology and disease. Review. J Invest Dermatol 2000;115:141-8.
12. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.
13. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). Review. J Am Acad Dermatol 1990;23(6 Pt 1):1039-58.
14. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993;128:357.
15. Martinez AE, Atherton DJ. High-dose systemic corticosteroids can arrest recurrences of severe mucocutaneous erythema multiforme. Paediatr Dermatol 2000;17:87-90.
16. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;205:503-12.
17. Rasmussen JE. Erythema multiforme in children. Response to treatment with systemic corticosteroids. Br J Dermatol 1976; 95:181-6.
18. Hewitt J, Ormerod AD. Toxic epidermal necrolysis treated with cyclosporin. Clin Exp Dermatol 1992;17:264-5.
19. Arévalo JM, Lorente JA, Gonzéles-Herrada C, Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-8.
20. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991;25(5 Pt 1):778-86.
21. Redondo P, de Felipe I, de la Pena A, Aramendia JM, Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136:645-6.
22. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-9.
23. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-61.
24. Viard I, Wehrli P, Bullani R, Schneider P et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282: 490-3.
25. Prins C, Kerdel FA, Padilla RS, Hunziker T et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
26. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
27. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. Review. N Engl J Med 1994;331:1272-85.
28. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
29. Fischer PR, Shigeoka AO. Familial occurrence of Stevens-Johnson syndrome. Am J Dis Child 1983;137:914-6.